business
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submissio...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Cornell rape case: New York governor removes DA from investigation, says Jane Doe was 'failed' by police and prosecutor
yahoo.com

US jobs market sees sharp slowdown in September
BBC Business

UK diesel price hits £2 a litre for first time, RAC says
BBC Business

'I was not going to let others die' - pilot of Flydubai flight describes cockpit attack by co-pilot
yahoo.com
Gold gets its festive shine back as lower prices lure Asian buyers
timesofindia.indiatimes.com